Akome’s Patent Pending DMT-based Drug Formulation: Targeting Parkinson’s Disease.

Akome’s AKO004 psychedelic drug formulation, for use in the treatment of Parkinson’s disease, is a composition comprising the psychedelic compound N, N-dimethyltryptamine (DMT), and, a specifically chosen, naturally occurring plant bioactive. Initial data analysis indicates that the AKO004 composition is safe and efficacious for use, and presents many positive properties which may counter or mitigate neurodegeneration including, anti-oxidant activity (through downregulation of adhesion molecules), oxidative stress suppression (through direct free radical scavenging), and upregulation of intracellular antioxidant defenses (e.g. enhancing glutathione levels). Additionally, initial data mapping also suggests that the compound may play a neuroprotective role in the brain, generally.

Parkinson’s disease is a progressive neurodegenerative disorder that is caused by degeneration of the nerve cells in the part of the brain called the substantia nigra, which controls movement. Neurodegeneration occurs when nerve cells in the brain or peripheral nervous system lose function over time and ultimately die.1 It is estimated that over 10 million people worldwide are living with Parkinson’s disease. Within the United States, it is further estimated that over 930,000 people live with Parkinson’s disease and approximately 60,000 more are diagnosed each year. An even more staggering statistic is that this number is predicted to rise to 1.2 million by 2030.

Although treatments may help relieve some of the physical or mental symptoms associated with neurodegenerative diseases, there is currently no way to slow disease progression and no know cures.

[1] https://www.parkinson.org/Understanding-Parkinsons/Statistics

Akome Biotech Ltd.

+1 604-691-7485

3123 – 595 Burrard Street
Vancouver, BC V7X 1J1